Ontology type: schema:ScholarlyArticle Open Access: True
2010-06-21
AUTHORSMartina Wieser, Stefan Sauerland, Dirk Arnold, Wolff Schmiegel, Anke Reinacher-Schick
ABSTRACTBackgroundThe role of peri-operative chemotherapy in patients with resected stage IV colorectal cancer (CRC) remains to be defined. This study was aimed at evaluating the effectiveness of peri-operative chemotherapy in patients with resected stage IV CRC by performing a meta-analysis of relevant trials.MethodsWe performed a literature search to identify trials comparing patients with stage IV CRC receiving peri-operative chemotherapy and surgery with patients undergoing surgery alone. The hazard ratio (HR) was estimated to assess any survival advantage of peri-operative chemotherapy.ResultsEight trials conducted on a total of 1174 patients were identified by a literature search. In these trials, HR estimates suggested that peri-operative chemotherapy yielded no survival advantage over surgery alone (HR, 0.94; 95%CI, 0.8-1.10; p = 0.43). In a subset analysis on intra-arterial chemotherapy alone, no survival benefit was evident (HR, 1.0; 95% CI, 0.84-1.21; p = 0.96; I2 = 30%), whereas in the trials involving systemic chemotherapy, the difference between the groups approached statistical significance (HR, 0.74; 95% CI, 0.53-1.04; p = 0.08; I2 = 0%). Both peri-operative treatment groups had a significant recurrence-free survival benefit (HR, 0.78; 95% CI, 0.65-0.95; P = 0.01 for hepatic arterial infusion; and HR, 0.75; 95% CI, 0.62-0.91; p = 0.003 for systemic therapy). The toxicities of chemotherapy were acceptable in most trials.ConclusionsThis is the first meta-analysis demonstrating the importance of peri-operative chemotherapy in the treatment of resected stage IV CRC. Although the results must be carefully interpreted because of some limitations, critical issues were identified that must be resolved by future studies. More... »
PAGES309
http://scigraph.springernature.com/pub.10.1186/1471-2407-10-309
DOIhttp://dx.doi.org/10.1186/1471-2407-10-309
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1028347950
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/20565923
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Colorectal Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Liver Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Meta-Analysis as Topic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Randomized Controlled Trials as Topic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Internal Medicine, Knappschaftskrankenhaus Bochum Langendreer, University of Bochum, Bochum, Germany",
"id": "http://www.grid.ac/institutes/grid.5570.7",
"name": [
"Department of Internal Medicine, Knappschaftskrankenhaus Bochum Langendreer, University of Bochum, Bochum, Germany"
],
"type": "Organization"
},
"familyName": "Wieser",
"givenName": "Martina",
"id": "sg:person.0700442405.73",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700442405.73"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Institute for Research in Operative Medicine, University of Witten/Herdecke, Cologne, Germany",
"id": "http://www.grid.ac/institutes/grid.412581.b",
"name": [
"Institute for Research in Operative Medicine, University of Witten/Herdecke, Cologne, Germany"
],
"type": "Organization"
},
"familyName": "Sauerland",
"givenName": "Stefan",
"id": "sg:person.01240721774.82",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240721774.82"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology and Oncology, University of Halle, Germany",
"id": "http://www.grid.ac/institutes/grid.9018.0",
"name": [
"Department of Hematology and Oncology, University of Halle, Germany"
],
"type": "Organization"
},
"familyName": "Arnold",
"givenName": "Dirk",
"id": "sg:person.01270303133.74",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270303133.74"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Institute for Clinical-Oncological Studies within P.U.R.E, University Bochum, Bochum, Germany",
"id": "http://www.grid.ac/institutes/grid.5570.7",
"name": [
"Department of Internal Medicine, Knappschaftskrankenhaus Bochum Langendreer, University of Bochum, Bochum, Germany",
"Institute for Clinical-Oncological Studies within P.U.R.E, University Bochum, Bochum, Germany"
],
"type": "Organization"
},
"familyName": "Schmiegel",
"givenName": "Wolff",
"id": "sg:person.0731736602.46",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731736602.46"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Institute for Clinical-Oncological Studies within P.U.R.E, University Bochum, Bochum, Germany",
"id": "http://www.grid.ac/institutes/grid.5570.7",
"name": [
"Department of Internal Medicine, Knappschaftskrankenhaus Bochum Langendreer, University of Bochum, Bochum, Germany",
"Institute for Clinical-Oncological Studies within P.U.R.E, University Bochum, Bochum, Germany"
],
"type": "Organization"
},
"familyName": "Reinacher-Schick",
"givenName": "Anke",
"id": "sg:person.01073166374.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073166374.14"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s004230050199",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1005575327",
"https://doi.org/10.1007/s004230050199"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.2165/00044011-200020050-00002",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1039478054",
"https://doi.org/10.2165/00044011-200020050-00002"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10434-001-0347-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015538540",
"https://doi.org/10.1007/s10434-001-0347-3"
],
"type": "CreativeWork"
}
],
"datePublished": "2010-06-21",
"datePublishedReg": "2010-06-21",
"description": "BackgroundThe role of peri-operative chemotherapy in patients with resected stage IV colorectal cancer (CRC) remains to be defined. This study was aimed at evaluating the effectiveness of peri-operative chemotherapy in patients with resected stage IV CRC by performing a meta-analysis of relevant trials.MethodsWe performed a literature search to identify trials comparing patients with stage IV CRC receiving peri-operative chemotherapy and surgery with patients undergoing surgery alone. The hazard ratio (HR) was estimated to assess any survival advantage of peri-operative chemotherapy.ResultsEight trials conducted on a total of 1174 patients were identified by a literature search. In these trials, HR estimates suggested that peri-operative chemotherapy yielded no survival advantage over surgery alone (HR, 0.94; 95%CI, 0.8-1.10; p = 0.43). In a subset analysis on intra-arterial chemotherapy alone, no survival benefit was evident (HR, 1.0; 95% CI, 0.84-1.21; p = 0.96; I2 = 30%), whereas in the trials involving systemic chemotherapy, the difference between the groups approached statistical significance (HR, 0.74; 95% CI, 0.53-1.04; p = 0.08; I2 = 0%). Both peri-operative treatment groups had a significant recurrence-free survival benefit (HR, 0.78; 95% CI, 0.65-0.95; P = 0.01 for hepatic arterial infusion; and HR, 0.75; 95% CI, 0.62-0.91; p = 0.003 for systemic therapy). The toxicities of chemotherapy were acceptable in most trials.ConclusionsThis is the first meta-analysis demonstrating the importance of peri-operative chemotherapy in the treatment of resected stage IV CRC. Although the results must be carefully interpreted because of some limitations, critical issues were identified that must be resolved by future studies.",
"genre": "article",
"id": "sg:pub.10.1186/1471-2407-10-309",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1024632",
"issn": [
"1471-2407"
],
"name": "BMC Cancer",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "10"
}
],
"keywords": [
"stage IV colorectal cancer",
"peri-operative chemotherapy",
"colorectal cancer",
"hazard ratio",
"survival benefit",
"survival advantage",
"recurrence-free survival benefit",
"literature search",
"resectable liver metastases",
"intra-arterial chemotherapy",
"toxicity of chemotherapy",
"systemic chemotherapy",
"liver metastases",
"relevant trials",
"randomized trials",
"subset analysis",
"chemotherapy",
"treatment groups",
"most trials",
"patients",
"systematic review",
"surgery",
"trials",
"statistical significance",
"HR estimates",
"cancer",
"future studies",
"treatment",
"group",
"metastasis",
"MethodsWe",
"ConclusionsThis",
"total",
"study",
"toxicity",
"benefits",
"review",
"search",
"differences",
"significance",
"role",
"effectiveness",
"ratio",
"importance",
"analysis",
"results",
"limitations",
"advantages",
"estimates",
"critical issue",
"issues"
],
"name": "Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials",
"pagination": "309",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1028347950"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/1471-2407-10-309"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"20565923"
]
}
],
"sameAs": [
"https://doi.org/10.1186/1471-2407-10-309",
"https://app.dimensions.ai/details/publication/pub.1028347950"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T16:58",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_516.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1186/1471-2407-10-309"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-10-309'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-10-309'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-10-309'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-10-309'
This table displays all metadata directly associated to this object as RDF triples.
187 TRIPLES
21 PREDICATES
86 URIs
75 LITERALS
14 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1186/1471-2407-10-309 | schema:about | N112869095efa446db2e070120e35fc6e |
2 | ″ | ″ | N345cf27afd514a4b9a0ab8216bb4fb0b |
3 | ″ | ″ | N58cddae3bc2941c994b3359eda74bf34 |
4 | ″ | ″ | N860d7625c43c497f98c63a72e2756dac |
5 | ″ | ″ | Na83c930f78644d43adb0fc6dbcc85c2f |
6 | ″ | ″ | Nbdb1fbde2df24206a1d6ae088842925a |
7 | ″ | ″ | Nd0049505f3b349adaeff49833f389b5c |
8 | ″ | ″ | anzsrc-for:11 |
9 | ″ | ″ | anzsrc-for:1112 |
10 | ″ | schema:author | Nddef94f33a804dc69a1e9e773c083fd5 |
11 | ″ | schema:citation | sg:pub.10.1007/s004230050199 |
12 | ″ | ″ | sg:pub.10.1007/s10434-001-0347-3 |
13 | ″ | ″ | sg:pub.10.2165/00044011-200020050-00002 |
14 | ″ | schema:datePublished | 2010-06-21 |
15 | ″ | schema:datePublishedReg | 2010-06-21 |
16 | ″ | schema:description | BackgroundThe role of peri-operative chemotherapy in patients with resected stage IV colorectal cancer (CRC) remains to be defined. This study was aimed at evaluating the effectiveness of peri-operative chemotherapy in patients with resected stage IV CRC by performing a meta-analysis of relevant trials.MethodsWe performed a literature search to identify trials comparing patients with stage IV CRC receiving peri-operative chemotherapy and surgery with patients undergoing surgery alone. The hazard ratio (HR) was estimated to assess any survival advantage of peri-operative chemotherapy.ResultsEight trials conducted on a total of 1174 patients were identified by a literature search. In these trials, HR estimates suggested that peri-operative chemotherapy yielded no survival advantage over surgery alone (HR, 0.94; 95%CI, 0.8-1.10; p = 0.43). In a subset analysis on intra-arterial chemotherapy alone, no survival benefit was evident (HR, 1.0; 95% CI, 0.84-1.21; p = 0.96; I2 = 30%), whereas in the trials involving systemic chemotherapy, the difference between the groups approached statistical significance (HR, 0.74; 95% CI, 0.53-1.04; p = 0.08; I2 = 0%). Both peri-operative treatment groups had a significant recurrence-free survival benefit (HR, 0.78; 95% CI, 0.65-0.95; P = 0.01 for hepatic arterial infusion; and HR, 0.75; 95% CI, 0.62-0.91; p = 0.003 for systemic therapy). The toxicities of chemotherapy were acceptable in most trials.ConclusionsThis is the first meta-analysis demonstrating the importance of peri-operative chemotherapy in the treatment of resected stage IV CRC. Although the results must be carefully interpreted because of some limitations, critical issues were identified that must be resolved by future studies. |
17 | ″ | schema:genre | article |
18 | ″ | schema:isAccessibleForFree | true |
19 | ″ | schema:isPartOf | N6a47c06dc0014c50894ac523e48ec383 |
20 | ″ | ″ | Nd79a04b31afa455faf4a1ea89e72c3c7 |
21 | ″ | ″ | sg:journal.1024632 |
22 | ″ | schema:keywords | ConclusionsThis |
23 | ″ | ″ | HR estimates |
24 | ″ | ″ | MethodsWe |
25 | ″ | ″ | advantages |
26 | ″ | ″ | analysis |
27 | ″ | ″ | benefits |
28 | ″ | ″ | cancer |
29 | ″ | ″ | chemotherapy |
30 | ″ | ″ | colorectal cancer |
31 | ″ | ″ | critical issue |
32 | ″ | ″ | differences |
33 | ″ | ″ | effectiveness |
34 | ″ | ″ | estimates |
35 | ″ | ″ | future studies |
36 | ″ | ″ | group |
37 | ″ | ″ | hazard ratio |
38 | ″ | ″ | importance |
39 | ″ | ″ | intra-arterial chemotherapy |
40 | ″ | ″ | issues |
41 | ″ | ″ | limitations |
42 | ″ | ″ | literature search |
43 | ″ | ″ | liver metastases |
44 | ″ | ″ | metastasis |
45 | ″ | ″ | most trials |
46 | ″ | ″ | patients |
47 | ″ | ″ | peri-operative chemotherapy |
48 | ″ | ″ | randomized trials |
49 | ″ | ″ | ratio |
50 | ″ | ″ | recurrence-free survival benefit |
51 | ″ | ″ | relevant trials |
52 | ″ | ″ | resectable liver metastases |
53 | ″ | ″ | results |
54 | ″ | ″ | review |
55 | ″ | ″ | role |
56 | ″ | ″ | search |
57 | ″ | ″ | significance |
58 | ″ | ″ | stage IV colorectal cancer |
59 | ″ | ″ | statistical significance |
60 | ″ | ″ | study |
61 | ″ | ″ | subset analysis |
62 | ″ | ″ | surgery |
63 | ″ | ″ | survival advantage |
64 | ″ | ″ | survival benefit |
65 | ″ | ″ | systematic review |
66 | ″ | ″ | systemic chemotherapy |
67 | ″ | ″ | total |
68 | ″ | ″ | toxicity |
69 | ″ | ″ | toxicity of chemotherapy |
70 | ″ | ″ | treatment |
71 | ″ | ″ | treatment groups |
72 | ″ | ″ | trials |
73 | ″ | schema:name | Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials |
74 | ″ | schema:pagination | 309 |
75 | ″ | schema:productId | N08b500ed47e34f5a922d6275c2704284 |
76 | ″ | ″ | N3e9e42014fc643b3a2a32a763b440a08 |
77 | ″ | ″ | Nb8bd9387c9a6424782ad9fb837f48cef |
78 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1028347950 |
79 | ″ | ″ | https://doi.org/10.1186/1471-2407-10-309 |
80 | ″ | schema:sdDatePublished | 2022-08-04T16:58 |
81 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
82 | ″ | schema:sdPublisher | N553f2d0a723d4bc19d9e02447e02a35f |
83 | ″ | schema:url | https://doi.org/10.1186/1471-2407-10-309 |
84 | ″ | sgo:license | sg:explorer/license/ |
85 | ″ | sgo:sdDataset | articles |
86 | ″ | rdf:type | schema:ScholarlyArticle |
87 | N0477ff6c11b34c0f9024c24f0a9a22fd | rdf:first | sg:person.0731736602.46 |
88 | ″ | rdf:rest | N3e7fe30d6f8f40a5848837e807896411 |
89 | N08b500ed47e34f5a922d6275c2704284 | schema:name | pubmed_id |
90 | ″ | schema:value | 20565923 |
91 | ″ | rdf:type | schema:PropertyValue |
92 | N112869095efa446db2e070120e35fc6e | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
93 | ″ | schema:name | Meta-Analysis as Topic |
94 | ″ | rdf:type | schema:DefinedTerm |
95 | N345cf27afd514a4b9a0ab8216bb4fb0b | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
96 | ″ | schema:name | Randomized Controlled Trials as Topic |
97 | ″ | rdf:type | schema:DefinedTerm |
98 | N3e7fe30d6f8f40a5848837e807896411 | rdf:first | sg:person.01073166374.14 |
99 | ″ | rdf:rest | rdf:nil |
100 | N3e9e42014fc643b3a2a32a763b440a08 | schema:name | dimensions_id |
101 | ″ | schema:value | pub.1028347950 |
102 | ″ | rdf:type | schema:PropertyValue |
103 | N521cebe22d7249879ad99298a6d4bdc5 | rdf:first | sg:person.01270303133.74 |
104 | ″ | rdf:rest | N0477ff6c11b34c0f9024c24f0a9a22fd |
105 | N553f2d0a723d4bc19d9e02447e02a35f | schema:name | Springer Nature - SN SciGraph project |
106 | ″ | rdf:type | schema:Organization |
107 | N58cddae3bc2941c994b3359eda74bf34 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
108 | ″ | schema:name | Antineoplastic Agents |
109 | ″ | rdf:type | schema:DefinedTerm |
110 | N60ae58124e024bc191cd06711ae0b950 | rdf:first | sg:person.01240721774.82 |
111 | ″ | rdf:rest | N521cebe22d7249879ad99298a6d4bdc5 |
112 | N6a47c06dc0014c50894ac523e48ec383 | schema:issueNumber | 1 |
113 | ″ | rdf:type | schema:PublicationIssue |
114 | N860d7625c43c497f98c63a72e2756dac | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
115 | ″ | schema:name | Treatment Outcome |
116 | ″ | rdf:type | schema:DefinedTerm |
117 | Na83c930f78644d43adb0fc6dbcc85c2f | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
118 | ″ | schema:name | Liver Neoplasms |
119 | ″ | rdf:type | schema:DefinedTerm |
120 | Nb8bd9387c9a6424782ad9fb837f48cef | schema:name | doi |
121 | ″ | schema:value | 10.1186/1471-2407-10-309 |
122 | ″ | rdf:type | schema:PropertyValue |
123 | Nbdb1fbde2df24206a1d6ae088842925a | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
124 | ″ | schema:name | Humans |
125 | ″ | rdf:type | schema:DefinedTerm |
126 | Nd0049505f3b349adaeff49833f389b5c | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
127 | ″ | schema:name | Colorectal Neoplasms |
128 | ″ | rdf:type | schema:DefinedTerm |
129 | Nd79a04b31afa455faf4a1ea89e72c3c7 | schema:volumeNumber | 10 |
130 | ″ | rdf:type | schema:PublicationVolume |
131 | Nddef94f33a804dc69a1e9e773c083fd5 | rdf:first | sg:person.0700442405.73 |
132 | ″ | rdf:rest | N60ae58124e024bc191cd06711ae0b950 |
133 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
134 | ″ | schema:name | Medical and Health Sciences |
135 | ″ | rdf:type | schema:DefinedTerm |
136 | anzsrc-for:1112 | schema:inDefinedTermSet | anzsrc-for: |
137 | ″ | schema:name | Oncology and Carcinogenesis |
138 | ″ | rdf:type | schema:DefinedTerm |
139 | sg:journal.1024632 | schema:issn | 1471-2407 |
140 | ″ | schema:name | BMC Cancer |
141 | ″ | schema:publisher | Springer Nature |
142 | ″ | rdf:type | schema:Periodical |
143 | sg:person.01073166374.14 | schema:affiliation | grid-institutes:grid.5570.7 |
144 | ″ | schema:familyName | Reinacher-Schick |
145 | ″ | schema:givenName | Anke |
146 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073166374.14 |
147 | ″ | rdf:type | schema:Person |
148 | sg:person.01240721774.82 | schema:affiliation | grid-institutes:grid.412581.b |
149 | ″ | schema:familyName | Sauerland |
150 | ″ | schema:givenName | Stefan |
151 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240721774.82 |
152 | ″ | rdf:type | schema:Person |
153 | sg:person.01270303133.74 | schema:affiliation | grid-institutes:grid.9018.0 |
154 | ″ | schema:familyName | Arnold |
155 | ″ | schema:givenName | Dirk |
156 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270303133.74 |
157 | ″ | rdf:type | schema:Person |
158 | sg:person.0700442405.73 | schema:affiliation | grid-institutes:grid.5570.7 |
159 | ″ | schema:familyName | Wieser |
160 | ″ | schema:givenName | Martina |
161 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700442405.73 |
162 | ″ | rdf:type | schema:Person |
163 | sg:person.0731736602.46 | schema:affiliation | grid-institutes:grid.5570.7 |
164 | ″ | schema:familyName | Schmiegel |
165 | ″ | schema:givenName | Wolff |
166 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731736602.46 |
167 | ″ | rdf:type | schema:Person |
168 | sg:pub.10.1007/s004230050199 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1005575327 |
169 | ″ | ″ | https://doi.org/10.1007/s004230050199 |
170 | ″ | rdf:type | schema:CreativeWork |
171 | sg:pub.10.1007/s10434-001-0347-3 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1015538540 |
172 | ″ | ″ | https://doi.org/10.1007/s10434-001-0347-3 |
173 | ″ | rdf:type | schema:CreativeWork |
174 | sg:pub.10.2165/00044011-200020050-00002 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1039478054 |
175 | ″ | ″ | https://doi.org/10.2165/00044011-200020050-00002 |
176 | ″ | rdf:type | schema:CreativeWork |
177 | grid-institutes:grid.412581.b | schema:alternateName | Institute for Research in Operative Medicine, University of Witten/Herdecke, Cologne, Germany |
178 | ″ | schema:name | Institute for Research in Operative Medicine, University of Witten/Herdecke, Cologne, Germany |
179 | ″ | rdf:type | schema:Organization |
180 | grid-institutes:grid.5570.7 | schema:alternateName | Department of Internal Medicine, Knappschaftskrankenhaus Bochum Langendreer, University of Bochum, Bochum, Germany |
181 | ″ | ″ | Institute for Clinical-Oncological Studies within P.U.R.E, University Bochum, Bochum, Germany |
182 | ″ | schema:name | Department of Internal Medicine, Knappschaftskrankenhaus Bochum Langendreer, University of Bochum, Bochum, Germany |
183 | ″ | ″ | Institute for Clinical-Oncological Studies within P.U.R.E, University Bochum, Bochum, Germany |
184 | ″ | rdf:type | schema:Organization |
185 | grid-institutes:grid.9018.0 | schema:alternateName | Department of Hematology and Oncology, University of Halle, Germany |
186 | ″ | schema:name | Department of Hematology and Oncology, University of Halle, Germany |
187 | ″ | rdf:type | schema:Organization |